GSK to produce 1 billion doses of adjuvant vaccine booster in 2021

A GSK logo is seen at the GSK research centre in Stevenage. (Reuters Photo)

British drugmaker GlaxoSmithKline Plc will expand production of vaccine efficacy boosters, or adjuvants, to produce 1 billion doses in 2021 for use in shots for COVID-19, the company said on Thursday.

For latest updates on coronavirus outbreak, click here

The company added it was in talks with governments on backing for the programme, which would effectively allow the expansion of the scale of production of future successful vaccines for the disease caused by the novel coronavirus.